David R Nelson, M.D.
Senior Vice President For Health Affairs, UF & President, UF Health
Department:
Senior Vice President for Health Affairs
Business Phone:
(352) 273-9400
Business Email:
nelsodr@ufl.edu
About David R Nelson
David R. Nelson, M.D., was appointed senior vice president for health affairs at the University of Florida and president of UF Health in April 2019. Dr. Nelson oversees operations for all components of UF Health, the university’s academic health center, with campuses in Gainesville and Jacksonville. This includes six health science colleges, nine interdisciplinary research centers, three hospital systems and more than 100 physician practices. He is committed to strategically position UF Health for smart growth; enhancing operations; supporting faculty, staff and students; and fostering a diverse, inclusive and equitable community. He also has continued to explore ways to optimize the speed of translation of research, bringing science to the bedside and to the community to improve patient care for individuals and populations. A professor of medicine and an expert in liver disease, Dr. Nelson’s record of academic achievement includes more than $100 million in research funding, more than 200 publications and multiple leadership roles in his area of expertise. He has co-authored the U.S. treatment guidelines for hepatitis C, the Clinical Pharmacogenetics Implementation Consortium guidelines for the use of genomic-guided hepatitis C (HCV) therapy, and represented the United States on the World Health Organization HCV guidelines committee. As a principal investigator on basic science, translational research and training grants, he developed an international real world data network (HCV-TARGET), a collaboration between clinician investigators, the pharmaceutical industry and the Food and Drug Administration (FDA). This transformed drug development pathways and led to faster and safer development of HCV therapies, resulting in his recognition by the FDA with the Regulatory Science Excellence Honor in 2018. In 2013, he was recognized for one of the Clinical Research Forum’s Top 10 Clinical Research Achievements and in 2014, he received the Association of American Medical Colleges’ Learning Health System Research Champion Award. He has continuously been recognized as one of America’s top physicians/gastroenterologists and has been the recipient of multiple exemplary teaching awards, an outstanding alumnus award from his medical school, a UF Research Foundation Professorship Award and a UF Term Professorship Award.
Dr. Nelson received his undergraduate degree from Dartmouth College and his medical degree from State University of New York Upstate University in Syracuse, New York. He completed a residency in internal medicine at the University of Massachusetts and obtained fellowship training in gastroenterology and hepatology at UF.
Teaching Profile
Courses Taught
2018
GMS7980 Research for Doctoral Dissertation
2015
GMS7093 Introduction to Clinical and Translational Research
2015
GMS6845 Clinical & Translational Research Practicum
Board Certifications
-
GastroenterologyAmerican Board of Gastroenterology
-
Internal MedicineAmerican Board of Internal Medicine
-
Transplant HepatologyAmerican Board of Internal Medicine
Clinical Profile
Specialties
- Gastroenterology
- Transplant Hepatology
Areas of Interest
- Cirrhosis
- Hepatitis C
- Liver Transplant
- Liver cancer – hepatocellular carcinoma
- Liver disease
- Liver disease – resources
Research Profile
Open Researcher and Contributor ID (ORCID)
0000-0001-6344-8548
Publications
2022
Evaluation of machine learning algorithms for predicting direct-acting antiviral treatment failure among patients with chronic hepatitis C infection.
Scientific reports.
12(1)
[DOI] 10.1038/s41598-022-22819-4.
[PMID] 36302828.
2022
Machine learning algorithms for predicting direct‐acting antiviral treatment failure in chronic hepatitis C: An HCV‐TARGET analysis
Hepatology.
76(2):483-491
[DOI] 10.1002/hep.32347.
[PMID] 35034373.
2022
Predictors of 30-day readmission and hospitalization costs of patients with hepatic encephalopathy in the US from 2010 to 2014.
Expert review of pharmacoeconomics & outcomes research.
22(3):409-415
[DOI] 10.1080/14737167.2021.1927717.
[PMID] 33985399.
2022
Sustainable and equivalent improvements in symptoms and functional well-being following viral cure from ledipasvir/sofosbuvir versus elbasvir/grazoprevir for chronic hepatitis C infection: Findings from the randomized PRIORITIZE trial.
Journal of viral hepatitis.
29(9):795-806
[DOI] 10.1111/jvh.13716.
[PMID] 35657133.
2021
A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study.
Hepatology (Baltimore, Md.).
74(6):2952-2964
[DOI] 10.1002/hep.32053.
[PMID] 34255381.
2021
Direct‐Acting Antiviral Treatment Use Remains Low Among Florida Medicaid Beneficiaries With Chronic Hepatitis C
Hepatology Communications.
5(2):203-216
[DOI] 10.1002/hep4.1634.
[PMID] 33553969.
2021
Do patients at high risk for Hepatitis C receive recommended testing? A retrospective cohort study of statewide Medicaid claims linked with OneFlorida clinical data.
Medicine.
100(50)
[DOI] 10.1097/MD.0000000000028316.
[PMID] 34918711.
2021
HCV testing: Order and completion rates among baby boomers obtaining care from seven health systems in Florida, 2015-2017.
Preventive medicine.
153
[DOI] 10.1016/j.ypmed.2020.106222.
[PMID] 32721414.
2021
High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence.
The American journal of gastroenterology.
116(9):1896-1904
[DOI] 10.14309/ajg.0000000000001332.
[PMID] 34465693.
2021
Linkage of resistance-associated substitutions in GT1 sofosbuvir + NS5A inhibitor failures treated with glecaprevir/pibrentasvir.
Journal of hepatology.
75(4):820-828
[DOI] 10.1016/j.jhep.2021.04.057.
[PMID] 34023351.
2021
Patient-reported outcomes 12 months after hepatitis C treatment with direct-acting antivirals: Results from the PROP UP study.
Liver international : official journal of the International Association for the Study of the Liver.
41(4):692-704
[DOI] 10.1111/liv.14781.
[PMID] 33387381.
2021
The Impact of Direct‐Acting Antiviral Therapy on End‐Stage Liver Disease Among Individuals with Chronic Hepatitis C and Substance Use Disorders
Hepatology.
74(2):566-581
[DOI] 10.1002/hep.31732.
[PMID] 33544904.
2021
Willingness to participate in research among black patients with liver disease: A national cross-sectional study.
Journal of viral hepatitis.
28(7):982-993
[DOI] 10.1111/jvh.13493.
[PMID] 33665897.
2020
Audience segmentation as a strategy for enhancing the use of research registries for recruiting patients into clinical trials.
Contemporary clinical trials communications.
17
[DOI] 10.1016/j.conctc.2019.100510.
[PMID] 31956721.
2020
DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort.
Journal of hepatology.
73(3):540-548
[DOI] 10.1016/j.jhep.2020.03.031.
[PMID] 32243960.
2020
Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting Antivirals.
Journal of general internal medicine.
35(4):1011-1020
[DOI] 10.1007/s11606-019-05394-9.
[PMID] 31659661.
2020
Patient-Centered Covid-19 Screening in a Community of Older Adults: Combining Educational and Research Components
NEJM Catalyst Innovations in Care Delivery.
2020
Reply to: “Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH)”.
Journal of hepatology.
72(3):592-593
[DOI] 10.1016/j.jhep.2019.11.015.
[PMID] 31889556.
2019
Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C.
JAMA network open.
2(6)
[DOI] 10.1001/jamanetworkopen.2019.4765.
[PMID] 31173117.
2019
Barriers to treatment of chronic hepatitis C with direct acting antivirals in an urban clinic.
Annals of hepatology.
18(2):304-309
[DOI] 10.1016/j.aohep.2018.06.001.
[PMID] 31053544.
2019
Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis.
Journal of viral hepatitis.
26(8):1027-1030
[DOI] 10.1111/jvh.13109.
[PMID] 30980576.
2019
Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy.
Gastroenterology.
157(6):1506-1517.e1
[DOI] 10.1053/j.gastro.2019.08.008.
[PMID] 31401140.
2019
Hepatitis C virus screening trends: A 2016 update of the National Health Interview Survey.
Cancer epidemiology.
60:112-120
[DOI] 10.1016/j.canep.2019.03.007.
[PMID] 30953971.
2019
Impact of All‐Oral Direct‐Acting Antivirals on Clinical and Economic Outcomes in Patients With Chronic Hepatitis C in the United States
Hepatology.
69(3):1032-1045
[DOI] 10.1002/hep.30303.
[PMID] 30289989.
2019
Is Interferon Therapy for Hepatitis C Infection a Treatable Risk Factor for Parkinson Disease?
JAMA neurology.
76(9):1006-1007
[DOI] 10.1001/jamaneurol.2019.1377.
[PMID] 31168561.
2019
Objectively measured pediatric obesity prevalence using the OneFlorida Clinical Research Consortium.
Obesity research & clinical practice.
13(1):12-15
[DOI] 10.1016/j.orcp.2018.10.002.
[PMID] 30391132.
2019
Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study.
Journal of hepatology.
71(3):486-497
[DOI] 10.1016/j.jhep.2019.04.016.
[PMID] 31096006.
2019
Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges.
Gastroenterology.
156(2):431-445
[DOI] 10.1053/j.gastro.2018.10.024.
[PMID] 30342035.
2019
Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV-TARGET Analysis.
Hepatology communications.
3(10):1388-1399
[DOI] 10.1002/hep4.1412.
[PMID] 31592494.
2018
A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study.
PloS one.
13(8)
[DOI] 10.1371/journal.pone.0196908.
[PMID] 30067745.
2018
Characterization of adult obesity in Florida using the OneFlorida clinical research consortium.
Obesity science & practice.
4(4):308-317
[DOI] 10.1002/osp4.274.
[PMID] 30151226.
2018
Chronic hepatitis C virus (HCV) increases the risk of chronic kidney disease (CKD) while effective HCV treatment decreases the incidence of CKD.
Hepatology (Baltimore, Md.).
67(2):492-504
[DOI] 10.1002/hep.29505.
[PMID] 28873225.
2018
Computable Eligibility Criteria through Ontology-driven Data Access: A Case Study of Hepatitis C Virus Trials.
AMIA … Annual Symposium proceedings. AMIA Symposium.
2018:1601-1610
[PMID] 30815206.
2018
Hepatitis C Virus Screening Trends: Serial Cross-Sectional Analysis of the National Health Interview Survey Population, 2013-2015.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
27(4):503-513
[DOI] 10.1158/1055-9965.EPI-17-0855.
[PMID] 29588306.
2018
Immunogenicity of the meningococcal polysaccharide conjugate vaccine in pediatric kidney transplant patients.
Pediatric nephrology (Berlin, Germany).
33(6):1037-1043
[DOI] 10.1007/s00467-017-3878-y.
[PMID] 29557497.
2018
Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
JACC. Cardiovascular interventions.
11(2):181-191
[DOI] 10.1016/j.jcin.2017.07.022.
[PMID] 29102571.
2018
Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection.
Scientific reports.
8(1)
[DOI] 10.1038/s41598-018-21303-2.
[PMID] 29453451.
2018
Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
16(11):1811-1819.e4
[DOI] 10.1016/j.cgh.2017.12.037.
[PMID] 29306043.
2017
A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma.
Molecular therapy : the journal of the American Society of Gene Therapy.
25(10):2299-2308
[DOI] 10.1016/j.ymthe.2017.08.005.
[PMID] 28865999.
2017
All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET database.
Alimentary pharmacology & therapeutics.
45(1):115-126
[DOI] 10.1111/apt.13823.
[PMID] 27790729.
2017
Consent2Share: an integrated broad consenting process for re-contacting potential study subjects.
Journal of clinical and translational research.
2(4):113-122
[PMID] 30873469.
2017
Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study.
Gut.
66(10):1844-1852
[DOI] 10.1136/gutjnl-2016-311609.
[PMID] 27418632.
2017
Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial.
The lancet. Gastroenterology & hepatology.
2(8):585-594
[DOI] 10.1016/S2468-1253(17)30116-4.
[PMID] 28576451.
2017
Evaluating the Efficacy of a Registry linked to a Consent to Re-Contact Program and Communication Strategies for Recruiting and Enrolling Participants into Clinical Trials.
Contemporary clinical trials communications.
8:62-66
[DOI] 10.1016/j.conctc.2017.08.005.
[PMID] 29503877.
2017
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment.
The New England journal of medicine.
377(15):1448-1455
[DOI] 10.1056/NEJMoa1704053.
[PMID] 29020583.
2017
Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial.
The Lancet. Infectious diseases.
17(10):1062-1068
[DOI] 10.1016/S1473-3099(17)30496-6.
[PMID] 28818546.
2017
HBV reactivation after HCV eradication: Deja Vu.
Liver international : official journal of the International Association for the Study of the Liver.
37(7)
[DOI] 10.1111/liv.13358.
[PMID] 28635166.
2017
Institutional profile: University of Florida Health Personalized Medicine Program.
Pharmacogenomics.
18(5):421-426
[DOI] 10.2217/pgs-2017-0028.
[PMID] 28346068.
2017
Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review.
Annals of internal medicine.
166(9):637-648
[DOI] 10.7326/M16-2575.
[PMID] 28319996.
2017
Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment.
Contemporary clinical trials.
57:58-68
[DOI] 10.1016/j.cct.2017.03.013.
[PMID] 28342989.
2017
Pragmatic trial of a Study Navigator Model (NAU) vs. Ambassador Model (N+) to increase enrollment to health research among community members who use illicit drugs.
Drug and alcohol dependence.
175:146-150
[DOI] 10.1016/j.drugalcdep.2016.12.031.
[PMID] 28419890.
2017
Public-Private Partnership: Targeting Real-World Data for Hepatitis C Direct-Acting Antivirals.
Gastroenterology.
153(3):626-631
[DOI] 10.1053/j.gastro.2017.07.025.
[PMID] 28757271.
2017
Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study.
Hepatology (Baltimore, Md.).
66(4):1090-1101
[DOI] 10.1002/hep.29258.
[PMID] 28504842.
2017
Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis – A pooled analysis.
Journal of hepatology.
67(4):700-707
[DOI] 10.1016/j.jhep.2017.06.011.
[PMID] 28645740.
2016
Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
63(6):776-783
[DOI] 10.1093/cid/ciw387.
[PMID] 27325691.
2016
Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response.
Gastroenterology.
151(6):1131-1140.e5
[DOI] 10.1053/j.gastro.2016.08.004.
[PMID] 27565882.
2016
Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection.
Gastroenterology.
150(2):419-29
[DOI] 10.1053/j.gastro.2015.10.013.
[PMID] 26497081.
2016
HCV Council–critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape.
Liver international : official journal of the International Association for the Study of the Liver.
36(4):488-502
[DOI] 10.1111/liv.12993.
[PMID] 26509462.
2016
HCV-TARGET Study Group. Effectiveness of Simeprevir plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients with HCV Genotype 1 Infection
Gastroenterology.
150(2):419-429
2016
HCVerso 1 and 2: faldaprevir with deleobuvit (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C genotype-1b infection
Clinical and Experimental Gastroenterology.
9:351-363
2016
HCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infection.
Clinical and experimental gastroenterology.
9:351-363
[PMID] 27920566.
2016
Hepatitis C virus: how to provide the best treatment with what I have.
Liver international : official journal of the International Association for the Study of the Liver.
36 Suppl 1:58-61
[DOI] 10.1111/liv.13004.
[PMID] 26725898.
2016
Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
22(1):24-33
[DOI] 10.1002/lt.24366.
[PMID] 26519873.
2016
L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions.
The Journal of infectious diseases.
213(8):1240-7
[DOI] 10.1093/infdis/jiv564.
[PMID] 26603202.
2016
On-Treatment HCV RNa As a Predictor of Sustained Virological Response in HCV Genotype 3-Infected Patients Treated With Daclatasvir and Sofosbuvir
Liver International.
36(11):1611-1618
[DOI] 10.1111/liv.13165.
2016
On-treatment HCV RNA as a predictor of sustained virological response in HCV genotype 3-infected patients treated with daclatasvir and sofosbuvir.
Liver international : official journal of the International Association for the Study of the Liver.
36(11):1611-1618
[DOI] 10.1111/liv.13165.
[PMID] 27188960.
2016
Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir.
PloS one.
11(8)
[DOI] 10.1371/journal.pone.0160668.
[PMID] 27494410.
2016
Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function.
Liver international : official journal of the International Association for the Study of the Liver.
36(6):807-16
[DOI] 10.1111/liv.13102.
[PMID] 26923436.
2016
Small-Molecule Inhibitor Sorafenib Regulates Immunoreactions By Inducing Survival and Differentiation of Bone Marrow Cells
Innate Immunity.
22(7):493-502
[DOI] 10.1177/1753425916659702.
2015
Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
13(4):772-9.e1
[DOI] 10.1016/j.cgh.2014.12.014.
[PMID] 25528010.
2015
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.
Hepatology (Baltimore, Md.).
61(4):1127-35
[DOI] 10.1002/hep.27726.
[PMID] 25614962.
2015
Clinical Trial Design for Alpha-1 Antitrypsin Deficiency: A Model for Rare Diseases.
Chronic obstructive pulmonary diseases (Miami, Fla.).
2(2):177-190
[DOI] 10.15326/jcopdf.2.2.2015.0132.
[PMID] 28848840.
2015
Designing a CTSA-Based Social Network Intervention to Foster Cross-Disciplinary Team Science.
Clinical and translational science.
8(4):281-9
[DOI] 10.1111/cts.12267.
[PMID] 25788258.
2015
Development of sofosbuvir for the treatment of hepatitis C virus infection.
Annals of the New York Academy of Sciences.
1358:56-67
[DOI] 10.1111/nyas.12832.
[PMID] 26235748.
2015
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.
Lancet (London, England).
386(10003):1537-45
[DOI] 10.1016/S0140-6736(15)00349-9.
[PMID] 26456905.
2015
Open-Label Study to Evaluate the Safety & Tolerability of Telaprevir in Combination With Sofosbuvir in Naive Subjects Infected With Hepatitis C Virus Genotype 1
Journal of Gastroenterology and Hepatology Research.
4(5):1599-1604
[DOI] 10.17554/j.issn.2224-3992.2015.04.535.
2015
Optimal interferon-free therapy in treatment-experienced chronic hepatitis C patients.
Liver international : official journal of the International Association for the Study of the Liver.
35 Suppl 1:65-70
[DOI] 10.1111/liv.12718.
[PMID] 25529089.
2015
Pharmacokinetics of hepatitis C treatment.
Pharmacogenomics Applications to Patient Care.
2015
Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET.
Journal of hepatology.
62(2):286-93
[DOI] 10.1016/j.jhep.2014.08.052.
[PMID] 25218788.
2015
Sustained Virologic Response Rates With Telaprevir-Based Therapy in Treatment-Naive Patients Evaluated by Race or Ethnicity
Journal of Clinical Gastroenterology.
49(4):336-344
[DOI] 10.1097/mcg.0000000000000150.
2015
Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir.
Alimentary pharmacology & therapeutics.
41(7):671-85
[DOI] 10.1111/apt.13095.
[PMID] 25627020.
2014
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens.
Clinical pharmacology and therapeutics.
95(2):141-6
[DOI] 10.1038/clpt.2013.203.
[PMID] 24096968.
2014
Clinical pharmacogenetics implementation: Approaches, successes, and challenges
American Journal of Medical Genetics Part C: Seminars in Medical Genetics.
166(1):56-67
[DOI] 10.1002/ajmg.c.31390.
[PMID] 24616371.
2014
Daclatasvir plus sofosbuvir for HCV infection.
The New England journal of medicine.
370(16):1560-1
[DOI] 10.1056/NEJMc1401726.
[PMID] 24738674.
2014
Direct-acting antiviral agents and the path to interferon independence.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
12(5):728-37
[DOI] 10.1016/j.cgh.2013.06.024.
[PMID] 23872239.
2014
Effects of Sofosbuvir-Based Treatment, With and Without Interferon, On Outcome and Productivity of Patients With Chronic Hepatitis C
Clinical Gastroenterology and Hepatology.
12(8):1349+-59.e13
[DOI] 10.1016/j.cgh.2013.11.032.
[PMID] 24316172.
2014
Genome-Wide Association Study To Characterize Serum Bilirubin Elevations in Patients With Hcv Treated With Gs-9256, An Hcv Ns3 Serine Protease Inhibitor
Antiviral Therapy.
19(7):679-686
[DOI] 10.3851/IMP2747.
[PMID] 24503447.
2014
Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
59(12):1666-74
[DOI] 10.1093/cid/ciu697.
[PMID] 25266287.
2014
Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS.
Liver international : official journal of the International Association for the Study of the Liver.
34(9):1428-44
[DOI] 10.1111/liv.12541.
[PMID] 24661807.
2014
Minimal Impact of Sofosbuvir and Ribavirin On Health Related Quality of Life in Chronic Hepatitis C (Ch-C)
Journal of hepatology.
60(4):741-747
[DOI] 10.1016/j.jhep.2013.12.006.
[PMID] 24333184.
2014
Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens
Hepatology.
59(6):2161-2169
[DOI] 10.1002/hep.27161.
2014
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.
The New England journal of medicine.
370(3):222-32
[DOI] 10.1056/NEJMoa1306227.
[PMID] 24428468.
2014
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
New England Journal of Medicine.
370(17):1594-1603
2014
VX-222, a non-nucleoside NS5B polymerase inhibitor, in telaprevir-based regimens for genotype 1 hepatitis C virus infection
European Journal of Gastroenterology & Hepatology.
26(7):761-773
[DOI] 10.1097/meg.0000000000000084.
2013
CC genotype donors for the interleukin-28B single nucleotide polymorphism are associated with better outcomes in hepatitis C after liver transplant.
Liver international : official journal of the International Association for the Study of the Liver.
33(1):72-8
[DOI] 10.1111/liv.12013.
[PMID] 23107586.
2013
Deep sequencing analysis of HCV NS3 resistance-associated variants and mutation linkage in liver transplant recipients.
PloS one.
8(7)
[DOI] 10.1371/journal.pone.0069698.
[PMID] 23922778.
2013
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection–a randomized trial.
Gastroenterology.
145(5):1035-1044.e5
[DOI] 10.1053/j.gastro.2013.07.051.
[PMID] 23924660.
2013
Efficacious versus effective: what’s in an adjective?
Simulation in healthcare : journal of the Society for Simulation in Healthcare.
8(3):191-2
[DOI] 10.1097/SIH.0b013e31829543d8.
[PMID] 23702588.
2013
Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma.
Cancer immunology, immunotherapy : CII.
62(4):737-46
[DOI] 10.1007/s00262-012-1380-8.
[PMID] 23223899.
2013
Institutional Profile: University of Florida & Shands Hospital Personalized Medicine Program: Clinical Implementation of Pharmacogenetics
Pharmacogenomics.
14:723-726
2013
Neutrophil-lymphocyte ratio predicts overall and recurrence-free survival after liver transplantation for hepatocellular carcinoma.
Hepatology research : the official journal of the Japan Society of Hepatology.
43(7):757-64
[DOI] 10.1111/hepr.12019.
[PMID] 23193965.
2013
New therapeutic strategies in HCV: second-generation protease inhibitors.
Liver international : official journal of the International Association for the Study of the Liver.
33 Suppl 1:80-4
[DOI] 10.1111/liv.12061.
[PMID] 23286850.
2013
OPA1 downregulation is involved in sorafenib-induced apoptosis in hepatocellular carcinoma.
Laboratory investigation; a journal of technical methods and pathology.
93(1):8-19
[DOI] 10.1038/labinvest.2012.144.
[PMID] 23108376.
2013
Patient-reported immunosuppression nonadherence 6 to 24 months after liver transplant: association with pretransplant psychosocial factors and perceptions of health status change.
Progress in transplantation (Aliso Viejo, Calif.).
23(4):319-28
[DOI] 10.7182/pit2013501.
[PMID] 24311395.
2013
Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial.
Journal of hepatology.
58(4):663-8
[DOI] 10.1016/j.jhep.2012.11.018.
[PMID] 23183528.
2013
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.
The New England journal of medicine.
368(20):1867-77
[DOI] 10.1056/NEJMoa1214854.
[PMID] 23607593.
2013
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.
The Lancet. Infectious diseases.
13(5):401-8
[DOI] 10.1016/S1473-3099(13)70033-1.
[PMID] 23499158.
2013
Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial.
Lancet (London, England).
381(9883):2100-7
[DOI] 10.1016/S0140-6736(13)60247-0.
[PMID] 23499440.
2013
The anti-viral effect of sorafenib in hepatitis C-related hepatocellular carcinoma.
Alimentary pharmacology & therapeutics.
37(1):91-7
[DOI] 10.1111/apt.12098.
[PMID] 23094860.
2012
Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients.
Annals of hepatology.
11(1):15-31
[PMID] 22166557.
2012
Diagnosis and management of patients with α1-antitrypsin (A1AT) deficiency.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
10(6):575-80
[DOI] 10.1016/j.cgh.2011.12.028.
[PMID] 22200689.
2012
Hepatitis C virus: a critical appraisal of new approaches to therapy.
Hepatitis research and treatment.
2012
[DOI] 10.1155/2012/138302.
[PMID] 23094146.
2012
Impact of transarterial therapy in hepatitis C-related hepatocellular carcinoma on long-term outcomes after liver transplantation.
American journal of clinical oncology.
35(4):345-50
[DOI] 10.1097/COC.0b013e31821631f6.
[PMID] 21552101.
2012
Levels of alanine aminotransferase confound use of transient elastography to diagnose fibrosis in patients with chronic hepatitis C virus infection.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
10(8):932-937.e1
[DOI] 10.1016/j.cgh.2012.01.015.
[PMID] 22289876.
2012
Liver test results do not identify liver disease in adults with α(1)-antitrypsin deficiency.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
10(11):1278-83
[DOI] 10.1016/j.cgh.2012.07.007.
[PMID] 22835581.
2012
Preparedness of the CTSA’s structural and scientific assets to support the mission of the National Center for Advancing Translational Sciences (NCATS).
Clinical and translational science.
5(2):121-9
[DOI] 10.1111/j.1752-8062.2012.00401.x.
[PMID] 22507116.
2012
Serum levels of soluble CD25 as a marker for hepatocellular carcinoma.
Oncology letters.
4(4):840-846
[PMID] 23205111.
2012
The Impact of Pre Transplant Transarterial Therapy in Hepatocellular Carcinoma
Higher Education Policy.
56:458A-459A
2012
The role of ribavirin in direct acting antiviral drug regimens for chronic hepatitis C.
Liver international : official journal of the International Association for the Study of the Liver.
32 Suppl 1:103-7
[DOI] 10.1111/j.1478-3231.2011.02711.x.
[PMID] 22212579.
2012
Trends in the prevalence of thrombocytopenia among individuals infected with hepatitis C virus in the United States, 1999-2008.
BMC research notes.
5
[DOI] 10.1186/1756-0500-5-142.
[PMID] 22414142.
2012
Unexpected maintenance of hepatitis C viral diversity following liver transplantation.
Journal of virology.
86(16):8432-9
[DOI] 10.1128/JVI.00749-12.
[PMID] 22623804.
2012
Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3.
Gut.
61(1):128-34
[DOI] 10.1136/gut.2010.236158.
[PMID] 21873466.
2011
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases
Hepatology.
54(4):1433-1444
2011
Boceprevir for untreated chronic HCV genotype 1 infection
New England Journal of Medicine.
364(13):1195-1206
[DOI] 10.1056/NEJMoa1010494.
[PMID] 21449783.
2011
Characterization of HCV interactions with Toll-like receptors and RIG-I in liver cells.
PloS one.
6(6)
[DOI] 10.1371/journal.pone.0021186.
[PMID] 21695051.
2011
Different radiosensitivity of CD4(+)CD25(+) regulatory T cells and effector T cells to low dose gamma irradiation in vitro.
International journal of radiation biology.
87(1):71-80
[DOI] 10.3109/09553002.2010.518208.
[PMID] 20958220.
2011
Expression of an IRF-3 fusion protein and mouse estrogen receptor, inhibits hepatitis C viral replication in RIG-I-deficient Huh 7.5 cells.
Virology journal.
8
[DOI] 10.1186/1743-422X-8-445.
[PMID] 21936899.
2011
Identification of the IFITM3 gene as an inhibitor of hepatitis C viral translation in a stable STAT1 cell line
Journal of Viral Hepatitis.
18(10):e523-e529
[DOI] 10.1111/j.1365-2893.2011.01452.x.
[PMID] 21914072.
2011
Is Model for End-Stage Liver Disease score associated with quality of life after liver transplantation?
Progress in transplantation (Aliso Viejo, Calif.).
21(3):207-14
[PMID] 21977881.
2011
Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model.
Laboratory investigation; a journal of technical methods and pathology.
91(4):598-608
[DOI] 10.1038/labinvest.2010.205.
[PMID] 21321535.
2011
Low prevalence of HBV DNA in the liver allograft from anti-HBc-positive donors: a single-center experience.
Clinical transplantation.
25(1):164-70
[DOI] 10.1111/j.1399-0012.2010.01211.x.
[PMID] 20156222.
2011
Once-Daily Psi-7977 Plus Peg/Rbv in Treatment-Naive Patients With Hcv Gt1: Robust End of Treatment Response Rates Are Sustained Post-Treatment
Higher Education Policy.
54:472A-473A
2011
PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
17(5):528-38
[DOI] 10.1002/lt.22271.
[PMID] 21506241.
2011
Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid.
Alimentary pharmacology & therapeutics.
33(2):235-42
[DOI] 10.1111/j.1365-2036.2010.04512.x.
[PMID] 21083674.
2011
Racial differences in hepatitis C treatment eligibility Hepatology
Hepatology.
54(1):70-78
[DOI] 10.1002/hep.24358.
[PMID] 21488082.
2011
Reactive oxygen species is essential for cycloheximide to sensitize lexatumumab-induced apoptosis in hepatocellular carcinoma cells.
PloS one.
6(2)
[DOI] 10.1371/journal.pone.0016966.
[PMID] 21347335.
2011
Response-guided telaprevir combination treatment for hepatitis C virus infection.
The New England journal of medicine.
365(11):1014-24
[DOI] 10.1056/NEJMoa1014463.
[PMID] 21916639.
2011
Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
9(8):688-93
[DOI] 10.1016/j.cgh.2011.04.029.
[PMID] 21640198.
2011
The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma.
Alimentary pharmacology & therapeutics.
34(2):205-13
[DOI] 10.1111/j.1365-2036.2011.04697.x.
[PMID] 21605146.
2011
The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naïve patients.
Liver international : official journal of the International Association for the Study of the Liver.
31 Suppl 1:53-7
[DOI] 10.1111/j.1478-3231.2010.02391.x.
[PMID] 21205138.
2011
University of Florida Clinical and Translational Science Institute: transformation and translation in personalized medicine.
Clinical and translational science.
4(6):400-2
[DOI] 10.1111/j.1752-8062.2011.00348.x.
[PMID] 22212220.
2010
Albinterferon Alfa-2b was not inferior to pegylated interferon-alpha in a randomized trial of patients with chronic hepatitis C virus genotype 1
Gastroenterology.
139(4):1257-1266
[DOI] 10.1053/j.gastro.2010.06.066.
[PMID] 20600013.
2010
Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3.
Gastroenterology.
139(4):1267-76
[DOI] 10.1053/j.gastro.2010.06.062.
[PMID] 20600017.
2010
Characterization of Anti-HCV Antibodies in IL-10-Treated Patients.
Viral immunology.
23(4):359-68
[DOI] 10.1089/vim.2009.0095.
[PMID] 20712480.
2010
Fatigue and Sleep Quality before and after Liver Transplantation
Progress in Transplantation.
20(3):221-233
[DOI] 10.1177/152692481002000305.
2010
Hepatitis C virus modulates human monocyte-derived dendritic cells.
Journal of viral hepatitis.
17(11):757-69
[DOI] 10.1111/j.1365-2893.2009.01231.x.
[PMID] 20051006.
2010
Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate
Gastroenterology.
139(5):1602-1611
[DOI] 10.1053/j.gastro.2010.07.059.
[PMID] 20723545.
2010
Identifying HCV genotype 2/3 patients who can receive a 16 week abbreviated course of peginterferon alfa-2a plus ribavirin
Hepatology.
2010
Identifying Hepatitis C Virus Genotype 2/3 Patients Who Can Receive a 16-Week Abbreviated Course of Peginterferon Alfa-2a (40Kd) Plus Ribavirin
Hepatology.
51(6):1897-1903
[DOI] 10.1002/hep.23331.
[PMID] 19937693.
2010
Influence of Serum and Soluble CD25 (sCD25) on Regulatory and Effector T-cell Function in Hepatocellular Carcinoma
Scandinavian Journal of Immunology.
72(4):293-301
[DOI] 10.1111/j.1365-3083.2010.02427.x.
[PMID] 20883314.
2010
Review article: the management of hepatocellular carcinoma.
Alimentary pharmacology & therapeutics.
31(4):461-76
[DOI] 10.1111/j.1365-2036.2009.04200.x.
[PMID] 19925500.
2010
Telaprevir for previously treated chronic HCV infection.
The New England journal of medicine.
362(14):1292-303
[DOI] 10.1056/NEJMoa0908014.
[PMID] 20375406.
2010
The use of cyclosporine for recurrent hepatitis C after liver transplant: a randomized pilot study.
Digestive diseases and sciences.
55(1):196-203
[DOI] 10.1007/s10620-009-0981-3.
[PMID] 19798576.
2010
Transfusion has no effect on recurrence in hepatitis C after liver transplantation.
Acta anaesthesiologica Scandinavica.
54(10):1224-32
[PMID] 21069900.
2009
A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naïve patients with chronic hepatitis C: ViSER1 results
Hepatology.
50(3):717-726
[DOI] 10.1002/hep.23073.
2009
A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma.
Hepatology international.
3(3):480-9
[DOI] 10.1007/s12072-009-9132-3.
[PMID] 19669251.
2009
Changes in B-lymphocyte stimulator protein levels during treatment with albinterferon alfa-2b in patients with chronic hepatitis C who have failed previous interferon therapy
Hepatology Research.
39(5):455-462
[DOI] 10.1111/j.1872-034x.2008.00475.x.
2009
Efficacy and Safety Results of Albinterferon Alfa-2B in Combination With Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 2 Or 3
Higher Education Policy.
50
2009
Gamma radiation alters the phenotype and function of CD4+CD25+ regulatory cells
.
33(5):565-571
2009
Hepatitis C drug development at a crossroads.
Hepatology (Baltimore, Md.).
50(4):997-9
[DOI] 10.1002/hep.23208.
[PMID] 19787813.
2009
Hepatitis C virus: a critical appraisal of approaches to therapy.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
7(4):397-414; quiz 366
[DOI] 10.1016/j.cgh.2008.11.016.
[PMID] 19114127.
2009
Hepatocellular Carcinoma Immunopathogenesis: Clinical Evidence for Global T Cell Defects and an Immunomodulatory Role for Soluble CD25 (sCD25)
Digestive Diseases and Sciences.
55(2):484-495
[DOI] 10.1007/s10620-009-0955-5.
[PMID] 19714465.
2009
Improving the Standard of Care for HCV Management: Available and Emerging Strategies for Optimal Patient Outcomes
PeerView CME Activity.
2009
Novel interferons for treatment of hepatitis c virus
Clinics in Liver Disease.
13(3):351-363
2009
Ribavirin: current role in the optimal clinical management of chronic hepatitis C.
Journal of hepatology.
50(2):402-11
[DOI] 10.1016/j.jhep.2008.11.006.
[PMID] 19091439.
2009
Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis C.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
7(2):212-8
[DOI] 10.1016/j.cgh.2008.10.035.
[PMID] 19061971.
2009
STAT-C: New therapies cannot get here fast enough
Current Hepatitis Reports.
8(2):73-80
[DOI] 10.1007/s11901-009-0011-0.
2009
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.
The New England journal of medicine.
360(18):1827-38
[DOI] 10.1056/NEJMoa0806104.
[PMID] 19403902.
2009
The natural history of hepatitis C cirrhosis after liver transplantation.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
15(9):1063-71
[DOI] 10.1002/lt.21784.
[PMID] 19718647.
2009
Using an immune functional assay to differentiate acute cellular rejection from recurrent hepatitis C in liver transplant patients
Liver Transplantation.
15(2):216-222
[DOI] 10.1002/lt.21666.
2008
Antiviral Activity of the Hcv Nucleoside Polymerase Inhibitor R7128 in Hcv Genotype 2 and 3 Prior Non-Responders: Interim Results of R7128 1500Mg Bid With Peg-Ifn and Ribavirin for 28 Days
Higher Education Policy.
48
2008
Dynamic evolution of therapy for chronic hepatitis C: how will novel agents be incorporated into the standard of care?
Antiviral therapy.
13(6):747-60
[PMID] 18839776.
2008
Is sonographic surveillance of polytetrafluorethylene-covered transjugular intrahepatic portosystemic shunts (TIPS) necessary? A single center experience comparing both types of stents
Clin Radiol .
63:1142-1148
2008
R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin
Hepatology.
48(2):385-397
[DOI] 10.1002/hep.22357.
2008
Ribavirin considerations in treatment optimization.
Antiviral therapy.
13 Suppl 1:23-30
[PMID] 18432160.
2007
Anti-hepatitis C virus activity of albinterferon alfa-2b in cell culture.
Hepatology research : the official journal of the Japan Society of Hepatology.
37(11):941-7
[PMID] 17573950.
2007
Current and future hepatitis C therapies
Archives of Medical Research.
38(6):678-690
2007
Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-γ1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis
Hepatology.
45(3):569-578
[DOI] 10.1002/hep.21561.
2007
Hepatitis C Virus Triggers Apoptosis of a Newly Developed Hepatoma Cell Line Through Antiviral Defense System
Gastroenterology.
133(5):1649-1659
[DOI] 10.1053/j.gastro.2007.09.017.
2007
Hepatocellular carcinoma cell supernatants increase expansion and function of CD4+CD25+ regulatory T cells
Laboratory Investigation.
87(6):582-590
[DOI] 10.1038/labinvest.3700540.
2007
Is early recurrence of hepatitis C associated with biliary anastamotic stricture after liver transplantation?
Transplantation.
84:1631-1635
2007
New Inhibitors of the HCV Life Cycle
Hot Topics in Viral Hepatitis.
7-13
2007
Peginterferon Alfa-2a and Ribavirin for 16 or 24 Weeks in HCV Genotype 2 or 3
New England Journal of Medicine.
357(2):124-134
2007
The failing liver
Audio-Digest Gastroenterology .
21(1)
2007
The Financial Burden of Transplantation: A Single-Center Survey of Liver and Kidney Transplant Recipients
Transplantation.
84(3):295-300
[DOI] 10.1097/01.tp.0000269797.41202.79.
2006
A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy.
Antiviral therapy.
11(1):35-45
[PMID] 16518958.
2006
Betaine Resolves Severe Alcohol-Induced Hepatitis and Steatosis Following Liver Transplantation
Digestive Diseases and Sciences.
51(7):1226-1229
[DOI] 10.1007/s10620-006-8038-3.
2006
Familial aggregation of insulin resistance in first-degree relatives of patients with nonalcoholic fatty liver disease.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
4(9):1162-9
[PMID] 16901766.
2006
Global transcriptional effects of PEG-IFN-α and ribavirin on peripheral blood cells obtained from patients with chronic hepatitis C
Hepatology Research.
36(4):277-287
[DOI] 10.1016/j.hepres.2006.08.007.
2006
Impact of implementation of the MELD scoring system on the prevalence and incidence of chronic renal disease following liver transplantation
Liver Transplantation.
12(5):754-761
[DOI] 10.1002/lt.20686.
2006
Late presentation of a biliary tract complication after right hepatic donation resulting in secondary biliary cirrhosis
Liver Transplantation.
12(2):306-309
[DOI] 10.1002/lt.20687.
2006
Longterm care of the liver transplant recipient.
Therapy of Digestive Disorders .
2006
Viral hepatitis: manifestations and management strategy.
Hematology. American Society of Hematology. Education Program.
375-80
[PMID] 17124086.
2005
A brief psychological intervention to improve adherence following transplantation.
Annals of transplantation.
10(1):52-7
[PMID] 15926754.
2005
A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients
Liver Transplantation.
11(8):941-949
[DOI] 10.1002/lt.20405.
2005
Defective Jak-Stat activation in hepatoma cells is associated with hepatitis C viral IFN-alpha resistance.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
25(9):528-39
[PMID] 16181053.
2005
Early hepatic stellate cell activation is associated with advanced fibrosis after liver transplantation in recipients with hepatitis C
Liver Transplantation.
11(10):1235-1241
[DOI] 10.1002/lt.20432.
2005
Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication.
Virology journal.
2
[PMID] 16146571.
2005
Pathogenesis of recurrent hepatitis C after liver transplantation
Current Hepatitis Reports.
4(4):138-144
2005
Reconstitution of hepatitis C virus-specific T-cell mediated immunity after liver transplantation
Hepatology.
41:72-81
2005
Short-Recovery Time After Percutaneous Liver Biopsy: Should We Change Our Current Practices?
Clinical Gastroenterology and Hepatology.
3(9):926-929
2004
An immunomodulatory role for CD4+CD25+ regulatory T lymphocytes in hepatitis C virus infection
Hepatology.
40(5):1062-1071
[DOI] 10.1002/hep.20454.
2004
Keratin 8 and 18 hyperphosphorylation is a marker of human liver disease progression
Hepatology.
40:459-466
2004
One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection
Liver Transplantation.
10(10):1240-1247
[DOI] 10.1002/lt.20238.
2004
Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C
Liver Transplantation.
10(2):199-207
[DOI] 10.1002/lt.20074.
2004
Tobacco use before and after liver transplantation: A single center survey and implications for clinical practice and research
Liver Transplantation.
10(3):412-417
[DOI] 10.1002/lt.20087.
2003
CD8+ T-cell interaction with HCV replicon cells: Evidence for both cytokine- and cell-mediated antiviral activity
Hepatology.
37(6):1335-1342
[DOI] 10.1053/jhep.2003.50207.
2003
Gene expression associated with interferon alfa antiviral activity in an HCV replicon cell line
Hepatology.
37(5):1180-1188
[DOI] 10.1053/jhep.2003.50184.
2003
Immunopathogenesis of Viral Hepatitis
Hepatitis: Index & Reviews .
1(2):3-4
2003
Lack of antiviral effect of a short course of mycophenolate mofetil in patients with chronic hepatitis C virus infection
Liver Transplantation.
9(1):57-61
[DOI] 10.1053/jlts.2003.50003.
2003
Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect.
Hepatology (Baltimore, Md.).
38(4):859-68
[PMID] 14512873.
2002
Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C
Liver Transplantation.
8(11):1000-1006
[DOI] 10.1053/jlts.2002.34968.
2002
Future Drug Development
Clinicians Companion VI: Experts Perspectives on Contemporary Clinical Issues in Hepatitis C.
21-24
2002
Interleukin-10 Inhibition of Nitric Oxide Biosynthesis Involves Suppression of CAT-2 Transcription
Nitric Oxide.
6(1):79-84
[DOI] 10.1006/niox.2001.0402.
2002
Liver transplantation for Hepatocellular carcinoma
Acta Minerva Surgical.
57(2):575-585
2001
Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
7(12):1064-70
[PMID] 11753908.
2001
Combined hepatic resection and radiofrequency ablation for hepatic adenomatosis
HPB Surgery .
2001
Host immune response in pathogenesis of hepatitis C
The Clinician’s Companion IV: Expert Perspectives on Contemporary Clinical Issues in Hepatitis C.
2001
The immunopathogenesis of hepatitis C virus infection.
Clinics in liver disease.
5(4):931-53
[PMID] 11685802.
2000
Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders.
Gastroenterology.
118(4):655-60
[PMID] 10734016.
2000
Interleukin-12 production in chronic hepatitis C infection
Journal of Hepatology.
33(1):169-169
1999
Determination of HCV-Specific Bulk CD8(+) Activity in Liver.
Methods in molecular medicine.
19:431-8
[DOI] 10.1385/0-89603-521-2:431.
[PMID] 21374384.
1999
Future options for the management of hepatitis C.
Seminars in liver disease.
19 Suppl 1:103-12
[PMID] 10349698.
1999
THE UTILITY OF NONINVASIVE SEROLOGIC MARKERS IN THE MANAGEMENT OF EARLY ALLOGRAFT REJECTION IN LIVER TRANSPLANTATION RECIPIENTS1
Transplantation.
68(2):247-253
[DOI] 10.1097/00007890-199907270-00015.
1998
Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C.
Hepatology (Baltimore, Md.).
28(1):225-30
[PMID] 9657116.
1998
Pathogenesis of chronic hepatitis C virus infection
Therapies for Viral Hepatitis.
1998
Pathogenesis of chronic hepatitis C virus infection.
Antiviral therapy.
3(Suppl 3):25-35
[PMID] 10726053.
1997
Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection.
Digestive diseases and sciences.
42(12):2487-94
[PMID] 9440625.
1997
Elevated serum interleukin 4 and interleukin 10 in patients with chronic hepatitis C virus infection
J Hepatol .
26:471-478
1997
Pathogenesis of hepatocellular damage in chronic hepatitis C virus infection.
Clinics in liver disease.
1(3):515-28, v
[PMID] 15560055.
1997
The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C.
Journal of immunology (Baltimore, Md. : 1950).
158(3):1473-81
[PMID] 9013994.
1997
Transforming growth factor-beta 1 in chronic hepatitis C.
Journal of viral hepatitis.
4(1):29-35
[PMID] 9031062.
1997
Treatment of chronic hepatitis C.
Comprehensive therapy.
23(4):269-76
[PMID] 9167919.
1996
Anti-GOR in chronic HCV patients with membranoproliferative glomerulonephritis.
Journal of hepatology.
24(2)
[PMID] 8907582.
1996
Host immune response in hepatitis C virus infection
Viral Hepatitis Reviews .
2:37-48
1995
alpha-Glutathione S-transferase as a marker of hepatocellular damage in chronic hepatitis C virus infection.
American journal of clinical pathology.
104(2):193-8
[PMID] 7639195.
1995
Variations of hepatitis C virus NS5B sequence (nucleotides 8261-8566) do not correlate with response to interferon-alpha therapy.
Journal of viral hepatitis.
2(6):285-92
[PMID] 8732174.
Grants
Sep 2023
ACTIVE
Assessing performance of a Hepatitis C Emergency Department (HepC-END) Screening Tool
Role: Co-Investigator
Funding: NATL INST OF HLTH NIDA
Jul 2023
ACTIVE
Capacity Building Projects to Support UF Health's Participation in the Health Systems Implementation Initiative
Role: Principal Investigator
Funding: PATIENT-CENTERED OUTCOMES RES INST
May 2020
– Jun 2023
COVID-19: Higher Education Emergency Relief Fund-Institutional Portion
Role: Project Manager
Funding: US DEPT OF EDUCATION
May 2018
– Apr 2023
Medicaid Prior Authorization Policies for Chronic Hepatitis C Treatment in Vulnerable Populations
Role: Other
Funding: NATL INST OF HLTH NIDA
Apr 2018
– Jul 2019
Together: Transforming and Translating Discovery to Improve Health
Role: Principal Investigator
Funding: NATL INST OF HLTH NCATS
Apr 2018
– Oct 2018
Stakeholder Engagement and Multi-Risk Assessment in Dental Care Settings
Role: Co-Investigator
Funding: UNIV OF ALABAMA BIRMINGHAM
via NATL INST OF HLTH NIDCR
Nov 2017
– Oct 2018
Safety of Direct Acting Antiviral Medications for Hepatitis C
Role: Co-Project Director/Principal Investigator
Funding: KAISER FOU RESEARCH INSTITUTE-Duplicate
via PATIENT-CENTERED OUTCOMES RES INST
Apr 2017
– Jun 2021
OoR CTSI Institutional Matching Support
Role: Project Manager
Funding: UF DIV OF SPONSORED RES MATCHING FUNDS
Apr 2017
– Jun 2020
COM CTSI Institutional Matching Support Year 3-4
Role: Principal Investigator
Funding: FL CLINICAL PRACTICE ASSO
Apr 2017
– Mar 2018
The National Dental PBRN FY18
Role: Co-Investigator
Funding: UNIV OF ALABAMA BIRMINGHAM
via NATL INST OF HLTH NIDCR
Apr 2017
– Mar 2018
Together: Transforming and Translating Discovery to Improve Health
Role: Principal Investigator
Funding: NATL INST OF HLTH NCATS
Mar 2017
– Mar 2021
A Phase 3b, Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir (G/P) +/- Ribavirin for GT1 Subjects with Chronic Hepatitis C Previously Treated with an NS5A Inhibitor + Sofosbuvir Therapy
Role: Principal Investigator
Funding: ABBVIE
Mar 2017
– Mar 2021
A Phase 3b, Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir (G/P) +/- Ribavirin for GT1 Subjects with Chronic Hepatitis C Previously Treated with an NS5A Inhibitor + Sofosbuvir Therapy
Role: Principal Investigator
Funding: ABBVIE
Aug 2016
– Jul 2017
The Patient-Reported Outcomes Project of HCV-TARGET (PROP up TARGET)
Role: Principal Investigator
Funding: UNIV OF NORTH CAROLINA CHAPEL HILL
via PATIENT-CENTERED OUTCOMES RES INST
Jul 2016
– Jun 2023
Collaborating to Advance Teaching and Learning of Science Educators and Students (CATALySES)
Role: Co-Investigator
Funding: NATL INST OF HLTH NIGMS
May 2016
– Aug 2021
THE PRIORITIZE STUDY: A PRAGMATIC, RANDOMIZED STUDY OF ORAL REGIMENS FOR HEPATITIS C: TRANSFORMING DECISION-MAKING FOR..
Role: Principal Investigator
Funding: Merck Sharp & Dohme
via PATIENT-CENTERED OUTCOMES RES INST
Apr 2016
– Mar 2017
TOGETHER: TRANSFORMING AND TRANSLATING DISCOVERY TO IMPROVE HEALTH ,
Role: Principal Investigator
Funding: NATL INST OF HLTH NCATS
Apr 2016
– Mar 2017
TOGETHER: TRANSFORMING AND TRANSLATING DISCOVERY TOIMPROVE HEALTH
Role: Project Manager
Funding: NATL INST OF HLTH NCATS
Jan 2016
– Mar 2022
Prioritize Study
Role: Principal Investigator
Funding: PATIENT-CENTERED OUTCOMES RES INST
Jan 2016
– Apr 2017
The National Dental PBRN
Role: Project Manager
Funding: UNIV OF ALABAMA BIRMINGHAM
via NATL INST OF HLTH
Dec 2015
– Dec 2018
A SINGLE ARM OPEN LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABT-493/ABT-530 IN RENALLY IMPAIRED ADULTS WITH…
Role: Principal Investigator
Funding: ABBVIE
Sep 2015
– Sep 2018
An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Low-Dose Ribavirin QD in Subjects with Genotype 1a Chronic Hepatitis C Virus Infection (GEODE II)
Role: Principal Investigator
Funding: ABBVIE
Aug 2015
– Jul 2018
Patient Reported Outcomes Project of HCV-Target (Prop up TARGET)
Role: Principal Investigator
Funding: UNIV OF NORTH CAROLINA CHAPEL HILL
via PATIENT-CENTERED OUTCOMES RES INST
Aug 2015
– Jul 2016
Validation of an Observer Reported Outcome (ObsRO) Measure of Home Functionality in Children with Pyruvate Dehydrogenase Complex Deficiency (PDCD)
Role: Project Manager
Funding: UNITED MITOCHONDRIAL DISEASE FOU
Jul 2015
ACTIVE
Florida Academic Cancer Center Alliance Seed Grants
Role: Project Manager
Funding: UF HEALTH SHANDS HOSPITAL
Jun 2015
– Jun 2023
A Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment with a Sofosbuvir-Based Regimen without Interferon for Chronic Hepatitis C Infection in Gilead-Sponsored Trials"
Role: Principal Investigator
Funding: GILEAD SCIENCES
Jun 2015
– Dec 2016
Evaluation of Baseline HCV Resistance mutations in Genotype1 patients initiating tretamnent in real-world settings
Role: Principal Investigator
Funding: JANSSEN SERVICES
May 2015
– Mar 2016
Together: Transforming and Translating Discovery to Improve Health
Role: Principal Investigator
Funding: NATL INST OF HLTH NCATS
May 2015
– Mar 2016
UF CTSI NRSA Training Core
Role: Project Manager
Funding: NATL INST OF HLTH
Apr 2015
– Jun 2021
Clinical and Translational Science Institute (CTSI)
Role: Project Manager
Funding: UF DIV OF SPONSORED RES MATCHING FUNDS
Feb 2015
– Feb 2018
A single arm, open label study to evaluate the efficacy and satety of ABT-493/ABT-530 in adults with chronic hepatitis C virus genotype 1,2,4,5 or 6 infection and compensated Cirrhosis
Role: Principal Investigator
Funding: ABBVIE
Nov 2014
– Jun 2020
PAYROLL OPERATING ACCOUNT
Role: Principal Investigator
Funding: UNIV OF FLORIDA
Jul 2014
– Oct 2017
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network-A Longitudinal, Observational Study
Role: Principal Investigator
Funding: BRISTOL MYERS SQUIBB CO
Jun 2014
– Sep 2018
BMS AI444-257 A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination with Sofosbuvir for the Treatment of Post-Liver Transplant Subjects with Chronic Hepatitis C
Role: Principal Investigator
Funding: BRISTOL MYERS SQUIBB CO
Mar 2014
ACTIVE
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network-A Longitudinal, Observational Study
Role: Principal Investigator
Funding: GILEAD SCIENCES
Feb 2014
– Feb 2017
MK-5172 'A PHASE II/II RANDOMIZED CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF THE COMBINATION REGIMEN OF MK-5172 AND MK-8742 IN SUBJECTS WITH HCV AND CHRONIC KIDNEY DISEASE'
Role: Principal Investigator
Funding: Merck Sharp & Dohme
Feb 2014
– Feb 2017
IDX-03YF '3-YEAR, Observ Study to Evaluate the Durability of Sustained Viral Response and the Kinetics of Antiviral-Resistant HCV in Subjects Who Participated in Studies of Idenix Anti-HCV, DAA'
Role: Principal Investigator
Funding: IDENIX PHARMACEUTICALS
Feb 2014
– Feb 2016
AI444-218 'A Phase 3 Evaluation of Daclatasvir and Sofosbuvir in Treatment Na?ve and Treatment Experienced Subjects with Genotype 3 Chronic Hepatitis C Infection'
Role: Principal Investigator
Funding: BRISTOL MYERS SQUIBB CO PHARM RES INST
Dec 2013
– Dec 2016
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network-A Longitudinal, Observational Study
Role: Principal Investigator
Funding: JANSSEN SERVICES
Oct 2013
– Dec 2020
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network-A Longitudinal, Observational Study
Role: Principal Investigator
Funding: ABBVIE
Oct 2013
– Oct 2016
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network- A Longitudinal, Observational Study
Role: Principal Investigator
Funding: NOVARTIS PHARMA AG
Oct 2013
– Oct 2016
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network-A Longitudinal, Observational Study
Role: Principal Investigator
Funding: ROCHE MOLECULAR SYSTEMS
Sep 2013
– Sep 2016
AbbVie M13-102 'A Follow-up Study to Assess Resistance and Durability of Response to AbbVie DAA Therapy in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the TX of Chronic HCV Infection' (AbbVie Protocol M13-102)
Role: Principal Investigator
Funding: ABBVIE
Jul 2013
– Dec 2019
Re-MATCH: Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor Adoptive Cell Therapy During Recovery from Myeloablative Chemotherapy and Hematopoietic Stem Cell Transplantation
Role: Project Manager
Funding: US ARMY MED RES ACQUISITION
Jun 2013
– Sep 2018
Genomic Medicine Implementation: The Personalized Medicine Program
Role: Project Manager
Funding: NATL INST OF HLTH NHGRI
Apr 2013
– Mar 2016
GS-US-337-0108 'A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir FDC ? RBV for 8 Wks and Sofosbuvir/Ledipasvir FDC Combo for 12 Wks in Tx-Na?ve Subjects with Chronic Genotype 1 HCV'
Role: Principal Investigator
Funding: GILEAD SCIENCES
Apr 2013
– Apr 2016
A Randomized Study to Evaluate the Safety and Efficacy of IDX179 in Combination with Simeprevir and Ribavirin for 12 Weeks in Subjects with Chronic Hepatitis C Infection'
Role: Principal Investigator
Funding: IDENIX PHARMACEUTICALS
Jan 2013
– Jan 2016
BI 201335 and BI 207127 Combination Therapy in Treatment -Naive HCV Patients
Role: Principal Investigator
Funding: BOEHRINGER INGELHEIM PHARM INC
Dec 2012
– Dec 2015
GS-US-337-0109 'G??A Phase 3, Multicenter, Randomized, Open-Label Study for Efficacy and Safety of Sofosbuvir/GS-5885 FDC -? Ribavirin for 12 & 24 Weeks in Treatment-Experienced Subjects w/Chronic Genotype 1 HCV InfectionG??
Role: Principal Investigator
Funding: GILEAD SCIENCES
Nov 2012
– Nov 2015
Nelson Abbott M13-099 'A Randomized, Open-label Study of ABT 450/Ritonavir/ABT-267 (ABT 450/r/ABT-267) and ABT-333 W RBV in Geno 1 (HCV) Infection and Human Cirrhosis (TURQUOISE-II)'
Role: Principal Investigator
Funding: ABBVIE
Oct 2012
– Oct 2015
Abbott M11-646 'A Randomized, Double-blind, Placebo-controlled Study to Evaluate te Efficacy and Safety of ABT-450/Ritonivair/ABT-267 (ABT-450/R/ABT-267) and ABT-333 Co-administered with RBV in Treatment-Naive Adults with Geno 1 Chronic (HCV) '
Role: Principal Investigator
Funding: ABBVIE
Oct 2012
– Dec 2019
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network- A Longitudinal, Observational Study
Role: Principal Investigator
Funding: Merck Sharp & Dohme
Sep 2012
– Sep 2015
GS-US-337-0102 'A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed-Dose Combination ? Ribavirin for 12 and 24 Weeks in Treatment-Na?ve Subjects with Chronic Genotype 1 HCV'
Role: Principal Investigator
Funding: GILEAD SCIENCES
Mar 2012
– Mar 2016
An Open-Label, Randomized Study to Evaluate the Efficacy and Safety of ABT-450 with Ritonavir (ABT-450/R) in Combination with ABT-267 With and Without ABT-333 and/or Ribavirin (RBV) in Treatment Naive Adults with Genotype 1 CHC
Role: Principal Investigator
Funding: ABBOTT LABORATORIES
Nov 2011
– Nov 2019
GS-US-248-0122, A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection
Role: Principal Investigator
Funding: GILEAD SCIENCES
Nov 2011
– Sep 2018
GS-US-248-0123 A Long Term Follow-up Registry Study of Subjects Who DidNot Achieve Sustained Virologic Response in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection
Role: Principal Investigator
Funding: GILEAD SCIENCES
Nov 2011
– Nov 2017
'A PHASE 3B STUDY OF 2 TX DURATIONS OF TELAPREVIR, PEGASYS, AND COPEGUS IN TREATMENT-NAIVE AND PRIOR RELAPSER SUBJECTS WITH GENOTYPE 1 CHRONIC HEPATITIS C AND IL28B CC GENOTYPE'
Role: Principal Investigator
Funding: VERTEX PHARMACEUTICALS
Oct 2011
ACTIVE
HCV-TARGET Primary Operating Project with subprojects
Role: Principal Investigator
Funding: UF DIV OF SPONSORED RESEARCH
Sep 2011
ACTIVE
HCV TARGET: Hepatitis C Therapeutic Registry and ResearchNetwork
Role: Principal Investigator
Funding: KADMON
Sep 2011
– Sep 2017
M11-652 'A Rand., Open-Label, Study Antiviral Activity, Safety, and PK, of ABT-450 w/ Ritonavir (ABT-450/r) in Combo with ABT-267 and/or ABT-333 W&W/O (RBV) for 8, 12 or 24 Weeks in Na?ve and Null Responder Subjects with Genotype 1 HCV
Role: Principal Investigator
Funding: ABBVIE
Jun 2011
– Jun 2017
'Parallel-Open-Label, Rand Study to Eval. Safety, Pharmacokinetics and Pharmacodynamics of PSI-7977 in Combination with BMS-790052 with or without Ribavirin in Treatment-Naive Subjects Chronically Infected with Hepatitis C Virus Genotypes 1, 2 OR 3
Role: Principal Investigator
Funding: BRISTOL MYERS SQUIBB CO
Dec 2010
– Dec 2016
GS-US-196-0123
Role: Principal Investigator
Funding: GILEAD SCIENCES
Aug 2010
– Aug 2016
BMSAI444010 'A Phase 2b Study of BMS-790052 in Combination with Peg-Interferon Alfa02a and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis C Genotype 1 and 4 Infection'
Role: Principal Investigator
Funding: BRISTOL MYERS SQUIBB CO
Mar 2010
– Mar 2016
VX09-222-103 'A Randomized, Parallel-Group, Dose-Ranging Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Antiviral Activity of VX-222 and Telaprevir in Combination With and Without Peginterferon-Alfa-2a (Pegasys) and Ribavirin (Copegus) in Trea
Role: Principal Investigator
Funding: VERTEX PHARMACEUTICALS
Mar 2010
ACTIVE
OPERATING ACCOUNT: HEPATOLOGY
Role: Principal Investigator
Funding: UNIV OF FLORIDA
Jan 2010
– Jan 2020
INDUSTRY SPONSORED CLINICAL TRIAL OPERATING ACCOUNT
Role: Principal Investigator
Funding: UNIV OF FLORIDA
Jul 2007
– Aug 2016
Clinical and Translational Science Institute
Role: Principal Investigator
Funding: UF RESEARCH FOU
Jul 2006
– Dec 2020
21st Century Research & Economic Development Investment Program (REDIP)
Role: Project Manager
Funding: STATE UNIV SYS OF FL BOARD OF GOVERNORS
Mar 2005
– Feb 2020
Lawton Family Liver Research – UFF Fund #008386
Role: Principal Investigator
Funding: UF FOUNDATION
Mar 2005
– Feb 2020
Res & Dev Gastroenterology – UFF Fund #002739
Role: Principal Investigator
Funding: UF FOUNDATION
Education
Fellowship – Gastroenterology
1996
·
University of Florida
Residency – Internal Medicine
1993
·
University of Massachusetts
Medical Degree
1990
·
SUNY Health Science Center
Contact Details
Phones:
- Business:
- (352) 273-9400
Emails:
- Business:
- nelsodr@ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100014
GAINESVILLE FL 32610 - Business Street:
-
J277 JHMHC
GAINESVILLE FL 32611